Response to: "Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication".

Rick, Jonathan W; Lio, Peter; Hsiao, Jennifer L; Shi, Vivian Y

Rick, Jonathan W; Lio, Peter; Hsiao, Jennifer L; Shi, Vivian Y.

Afiliación

Rick JW; Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Lio P; Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, Illinois.
Hsiao JL; Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.
Shi VY; Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: vivian.shi.publications@gmail.com.

J Am Acad Dermatol ; 87(1): e33-e34, 2022 07.

Article en En | MEDLINE | ID: mdl-35307489

Asunto(s)

Inhibidores de las Cinasas Janus; Comunicación; Humanos; Inhibidores de las Cinasas Janus/efectos adversos; Estados Unidos; United States Food and Drug Administration

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de las Cinasas Janus Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Am Acad Dermatol Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google